Ftse Mib
34.660,38
-0,50%
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
NASDAQ
17.133,13
-0,23%
Bitcoin
69.349,96
0,03%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ 2seventy bio Inc (TSVT) 2seventy bio Inc (TSVT) Notizie

TSVT

2seventy bio (TSVT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TSVT
DataOraFonteTitoloSimboloCompagnia
06/06/202401:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSVT2seventy bio Inc
23/05/202413:00Business Wire2seventy bio to Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
09/05/202422:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TSVT2seventy bio Inc
08/05/202413:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
08/05/202413:00Business Wire2seventy bio Reports First Quarter Financial Results and Recent Operational ProgressNASDAQ:TSVT2seventy bio Inc
03/05/202413:00Business Wire2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:TSVT2seventy bio Inc
05/04/202415:05Business WireU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyNASDAQ:TSVT2seventy bio Inc
01/04/202413:30Business Wire2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to RegeneronNASDAQ:TSVT2seventy bio Inc
20/03/202422:04Business Wire2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of DirectorsNASDAQ:TSVT2seventy bio Inc
15/03/202423:27Business WireFDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of TherapyNASDAQ:TSVT2seventy bio Inc
07/03/202422:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TSVT2seventy bio Inc
05/03/202413:00Business Wire2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational ProgressNASDAQ:TSVT2seventy bio Inc
01/03/202413:00Business Wire2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
05/02/202412:59Business WireBristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 StudyNASDAQ:TSVT2seventy bio Inc
02/02/202422:54Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:TSVT2seventy bio Inc
30/01/202415:25AllPennyStocks.comBiotech Shares Soar Premarket On Sale Of R&D AssetsNASDAQ:TSVT2seventy bio Inc
30/01/202413:01Business Wire2seventy bio Announces New Strategic Path ForwardNASDAQ:TSVT2seventy bio Inc
05/01/202422:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TSVT2seventy bio Inc
12/12/202301:30Business WireAbecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3NASDAQ:TSVT2seventy bio Inc
11/12/202313:00Business Wire2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)NASDAQ:TSVT2seventy bio Inc
06/12/202320:00Business Wire2seventy bio Reiterates Commitment to Maximizing Shareholder ValueNASDAQ:TSVT2seventy bio Inc
01/12/202312:49Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TSVT2seventy bio Inc
01/12/202312:40Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:TSVT2seventy bio Inc
20/11/202320:31Dow Jones NewsTrending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDANASDAQ:TSVT2seventy bio Inc
20/11/202314:30Dow Jones News2seventy Bio Shares Fall Premarket on Abecma Expansion DelayNASDAQ:TSVT2seventy bio Inc
20/11/202313:56Dow Jones NewsFDA Advisory Panel to Meet on Earlier Use of Abecma From Bristol, 2seventyNASDAQ:TSVT2seventy bio Inc
20/11/202312:59Business WireBristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple MyelomaNASDAQ:TSVT2seventy bio Inc
14/11/202313:00Business Wire2seventy bio Reports Third Quarter Financial Results and Recent Operational ProgressNASDAQ:TSVT2seventy bio Inc
10/11/202313:00Business Wire2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023NASDAQ:TSVT2seventy bio Inc
12/09/202313:00Business Wire2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial RunwayNASDAQ:TSVT2seventy bio Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TSVT

La tua Cronologia

COIN
YLCETH
YoloCash
ASX
PHWDA
AQSE
ALSP
Ace Liberty & Stone
NYSE
USE
USCF ETF Trust
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network